---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-088239"
form_type: "8-K"
ticker: null
cik: "0001780097"
company_name: "Baudax Bio, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T08:10:19.709355+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Baudax Bio transfers ANJESO assets to Alkermes, amends credit, issues warrants

## Summary
- Transferred ANJESO patents, trademarks, equipment, data to Alkermes; NDA withdrawal and potential later transfer; all related agreements terminated with no further payments.
- Amended credit agreement: lenders consented to asset transfer, released liens on transferred assets, reduced minimum liquidity covenant to $2.5M.
- Issued 785,026 warrants to MAM Eagle Lender at $1.8951/share, 10-year term, with registration rights.
- Will pay $567,500 amendment fee in 12 monthly installments to lenders.

## SEC filing metadata
- accession: 0001193125-23-088239
- form_type: 8-K
- cik: 0001780097
- company_name: Baudax Bio, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1780097/000119312523088239/0001193125-23-088239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1780097/000119312523088239/d454236d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-088239
- JSON: https://secwatch.observer/filing/0001193125-23-088239.json
- Plain text: https://secwatch.observer/filing/0001193125-23-088239.txt

## Key facts
- M&A Transactions
  Baudax Bio, Inc. completed a disposition involving Alkermes Pharma Ireland Limited for no further payments of any kind (closed 2023-03-29).
  - Action: disposition
  - Counterparty: Alkermes Pharma Ireland Limited
  - Consideration: no further payments of any kind
  - Closing: 2023-03-29
  source text: Alkermes Agreement On March 29, 2023, the Company entered into an Asset Transfer Agreement with Alkermes Pharma Ireland Limited (“Alkermes”) (the “Transfer Agreement”). Under the terms of the Transfer Agreement, the Company transferred the rights to certain patents, trademarks, equipment, data and other rights related to ANJESO ® (the “Assets”) to Alkermes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1780097/000119312523088239/0001193125-23-088239-index.htm
- Material Agreements
  Baudax Bio, Inc. amended Amendment No. 5 and Consent to Credit Agreement with Wilmington Trust, National Association, solely in its capacity as administrative and collateral agent and the lenders party thereto (effective 2023-03-29).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Wilmington Trust, National Association, solely in its capacity as administrative and collateral agent and the lenders party thereto
  - Effective: 2023-03-29
  source text: On March 29, 2023 (the “Closing Date”), Baudax Bio, Inc. (the “Company”) entered into that certain Amendment No. 5 and Consent to Credit Agreement (the “Amendment”) by and among the Company, Baudax Bio N.A. LLC (“Baudax LLC”), Baudax Bio Limited, Wilmington Trust, National Association, solely in its capacity as administrative and collateral agent (the “Agent”) and the lenders party thereto (the “Lenders”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1780097/000119312523088239/0001193125-23-088239-index.htm
- Material Agreements
  Baudax Bio, Inc. entered into Asset Transfer Agreement with Alkermes Pharma Ireland Limited (effective 2023-03-29).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Alkermes Pharma Ireland Limited
  - Effective: 2023-03-29
  source text: On March 29, 2023, the Company entered into an Asset Transfer Agreement with Alkermes Pharma Ireland Limited (“Alkermes”) (the “Transfer Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1780097/000119312523088239/0001193125-23-088239-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.